Related coverage linked through entity extraction aliases.
Feb 13, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
Apr 21, 2025
Orforglipron, an oral non-peptide GLP-1R partial agonist developed by Chugai and Eli Lilly, has reported positive Phase III data for obesity and type 2 diabetes, representing a shift from injectable peptides to oral small molecules in the GLP-1R space.
Dec 12, 2025
Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.
Dec 19, 2025
Eli Lilly has built $1.5 billion in pre-launch inventory of oral weight loss drug orforglipron ahead of an April 2026 FDA decision, while Phase 3 data showed the drug maintained weight loss after switching from injectables.
Feb 13, 2026
Eli Lilly has accumulated $1.5 billion in pre-launch inventory of its experimental oral weight-loss drug orforglipron ahead of an expected FDA decision in April, up from $550 million last year.
Feb 13, 2026
Dr Reddy's and Biocon plan to launch generic versions of Novo Nordisk's weight-loss drugs at up to 60% below branded prices as semaglutide patents expire, targeting a global market projected to reach $150 billion by the early 2030s.
Feb 13, 2026
Researchers at the University of Pittsburgh School of Medicine discovered that protecting VAT macrophages in visceral fat tissue can improve insulin sensitivity, offering a potential new therapeutic approach for type 2 diabetes.
